• en
  • fr
Connect with Pendopharm on LinkedIn
Careers
Drug safety
Pendopharm
  • About Us
  • Prescription products
    • Gastroenterology
    • Orthopedics
    • Specialty medicine
  • Consumer products
    • Allergy
    • Cough, cold & sinus
    • Gastroenterology
    • Others
  • Partnerships
  • Newsroom
  • Contact Us
Connect with Pendopharm on LinkedIn
  • en
  • fr
Pendopharm
  • en
  • fr
Connect with Pendopharm on LinkedIn

Health Canada Approves Visbiome Probiotic for Irritable Bowel Syndrome

Newsroom

    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • October 10, 2017

    Health Canada Approves Visbiome Probiotic for Irritable Bowel Syndrome

    Read More
  • October 5, 2017

    PENDOPHARM launches GLATECT, a new treatment option for MS patients

    Read More
  • September 28, 2017

    Introducing the New LAX-A product line for relief of occasional constipation

    Read More
  • September 28, 2017

    With Lax-A-Day, you don’t need to spend your life in the bathroom!

    Read More
  • September 22, 2017

    PENDOPHARM, a division of Pharmascience Inc., Invests in Ontario based Edesa Biotech and Licenses Three Novel Anorectal Treatments for Canada

    Read More
  • Prescription products
    • Gastroenterology
    • Orthopedics
    • Specialty medicine
  • Consumer products
    • Allergy
    • Cough, cold & sinus
    • Gastroenterology
    • Others
  • About Us
  • Partnerships
  • Newsroom
  • Contact Us
  • Disposing Unused/expired Medications
  • Terms and Conditions

Search by Product Name

Back to Top